Clay Siegal, CEO of Seattle Genetics Focusing on Fighting Cancer

Seattle is the home of the headquarters of Seattle Genetics. The building that is home to the office is a building that has a triangular sculpture that has the appearance of being constructed from Lego bricks of a human antibody. This fits the company whose main focus is studying and manipulating human antibodies that go into drugs.

Seattle Genetics was founded in 1998 and has a strategy to become large enough to become a pharmaceutical company within the biotech community in the city. The antibodies are used as a therapy treatment plan for diseases like cancer since the antibodies are able to destroy the cancer cells from inside the body.

The company’s co-founder, CEO, chairman and president Clay Siegall says o the company’s long list of drugs it is proof of wanting to enlarge the company. Currently, it is worth $10 billion, employees 900 people and is the largest biotech company in Washington. Mr. Clay Siegall said of the company they want to move beyond being the largest biotech company and focus on drug development. This would allow the company to deal with the complications involving the international market in case of new drugs. To this end, Mr. Siegall withdrew a bid of $2 million in May after the February bid to obtain worldwide rights to commercialize a cancer drug. This drug is under development by Immunomedics based in New Jersey.

The Seattle Genetics company has eleven other drugs in the works and sent $376 million in research. This focus is on an antibody conjugate drug or ADC, which targets the antigens or protein molecules that cause the immune system to produce antibodies. This is able to deliver what the company refers to as smart-bombs that can kill cancer cells but does not harm the tissue. Then a second drug is known as 33A and is crafted to target acute myeloid leukemia. Though, the testing of this drug was stopped after four patient deaths.

Clay Siegall is the founder of Seattle Genetics in 1998, as well as chairman, CEO, and president of the biotech company. He attended the University of Maryland wearing a BS in Zoology and then attended George Washington University earning a Ph.D. in Genetics.

Mr. Siegall was employed at Bristol-Myers Squibb Pharmaceutical Research Institute from 1991-1997. He also worked at the National Cancer Institute from 1988 to 1991. He serves as director of two privately held biotech companies, Alder Biopharmaceuticals Inc and Marina Therapeutics.